Figure 4From: The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatmentSimulated lumefantrine pharmacokinetic parameters at different dosage scenarios for HIV-malaria-co-infected- patients on efavirenz-based treatment. The box and whiskers represent 95% confidence interval of the mean and the first and third quartiles of the simulated.Back to article page